Protuoso Biosciences raised $9.5 million in a seed round to build a hub-and-spoke antibody developer model. The funding positions the company to support antibody discovery and development by leveraging a centralized technology and partner network approach. The hub-and-spoke structure aims to increase throughput by distributing specific discovery or engineering tasks across specialized groups while maintaining shared standards and an integrated pipeline strategy. Investors will likely focus on how Protuoso converts early discovery into preclinical candidates and how it manages IP and partner execution risk. Seed financing at this level suggests confidence in the platform’s ability to generate translational antibodies, but the next key milestones will be lead selection, IND-enabling progress, and evidence of repeatable candidate generation across targets.